Literature DB >> 26711755

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.

Sujata M Bhavnani1, Paul G Ambrose2, Jeffrey P Hammel2, Christopher M Rubino2, George L Drusano3.   

Abstract

The choice of an antimicrobial agent must balance optimization of efficacy endpoints with the minimization of safety events. The risk versus benefit of daptomycin for patients with Staphylococcus aureus bacteremia with or without infective endocarditis receiving daptomycin at 6, 8, and 10 mg/kg of body weight/day was assessed. The relationships between the area under the concentration-time curve over 24 h (AUC)/MIC ratio and both clinical response and time to decreased susceptibility were evaluated using data from patients with such infections who received daptomycin at 6 mg/kg/day. Using these relationships, plus the previously identified relationship between the minimum concentration and an elevation in the creatine phosphokinase (CPK) concentration (CPK elevation) (S. M. Bhavnani, C. M. Rubino, P. G. Ambrose, and G. L. Drusano, Clin Infect Dis 50:1568-1574, 2010) and Monte Carlo simulation, the probability of each outcome by MIC for daptomycin at 6, 8, and 10 mg/kg/day was calculated. The function for exposure-response relationships for clinical response (P = 0.06) and time to decreased susceptibility (P = 0.01) resembled U and inverted U shapes, respectively. Multivariable analyses demonstrated AUC/MIC ratio, creatinine clearance, albumin concentration, and disease category to be predictors of clinical response. The results of simulations failed to demonstrate large improvements in the probabilities of clinical success among cohorts of simulated patients defined by the above-described predictive factors or the probability of decreased susceptibility at 30 days when the daptomycin dose was increased from 6 to 10 mg/kg/day. The probability of CPK elevation increased from 0.073 to 0.156 over this dose range. These data can be used to inform risk-versus-benefit decisions for daptomycin dose selection in patients with S. aureus bacteremia with or without infective endocarditis. The risk of CPK elevation, which is reversible, should be weighed in the context of the mortality and severe morbidity associated with these types of serious staphylococcal infections.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26711755      PMCID: PMC4776011          DOI: 10.1128/AAC.02967-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Authors:  Nelson Jumbe; Arnold Louie; Robert Leary; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; Christopher Freeman; James B Kahn; Karen Bush; Michael N Dudley; Michael H Miller; George L Drusano
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

2.  The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance.

Authors:  Vincent H Tam; Arnold Louie; Mark R Deziel; Weiguo Liu; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

Review 5.  The selection of appropriate dosages for intravenous ciprofloxacin.

Authors:  R M Echols
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

6.  Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.

Authors:  C A Peloquin; T J Cumbo; D E Nix; M F Sands; J J Schentag
Journal:  Arch Intern Med       Date:  1989-10

7.  Once-daily dosing in dogs optimizes daptomycin safety.

Authors:  F B Oleson; C L Berman; J B Kirkpatrick; K S Regan; J J Lai; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 8.  Back to the future: using aminoglycosides again and how to dose them optimally.

Authors:  George L Drusano; Paul G Ambrose; Sujata M Bhavnani; Joseph S Bertino; Ann N Nafziger; Arnold Louie
Journal:  Clin Infect Dis       Date:  2007-08-08       Impact factor: 9.079

9.  High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.

Authors:  Manuela Carugati; Arnold S Bayer; Josè M Miró; Lawrence P Park; Armenio C Guimarães; Athanasios Skoutelis; Claudio Q Fortes; Emanuele Durante-Mangoni; Margaret M Hannan; Francisco Nacinovich; Nuria Fernández-Hidalgo; Paolo Grossi; Ru-San Tan; Thomas Holland; Vance G Fowler; Ralph G Corey; Vivian H Chu
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

10.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more
  8 in total

1.  Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.

Authors:  Brian VanScoy; Jennifer McCauley; Sujata M Bhavnani; Evelyn J Ellis-Grosse; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

2.  Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review.

Authors:  Farnaz Foolad; Brandie D Taylor; Samuel A Shelburne; Cesar A Arias; Samuel L Aitken
Journal:  J Antimicrob Chemother       Date:  2018-09-01       Impact factor: 5.790

Review 3.  Clinical Pharmacokinetics of Daptomycin.

Authors:  Nicolas Gregoire; Alexia Chauzy; Julien Buyck; Blandine Rammaert; William Couet; Sandrine Marchand
Journal:  Clin Pharmacokinet       Date:  2020-12-14       Impact factor: 6.447

4.  Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight.

Authors:  Ashley N Fox; Winter J Smith; Katherine E Kupiec; Stephanie J Harding; Beth H Resman-Targoff; Stephen B Neely; Bryan P White; Ryan E Owens
Journal:  Ther Adv Infect Dis       Date:  2019-01-30

Review 5.  Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents.

Authors:  M L Rizk; S M Bhavnani; G Drusano; A Dane; A E Eakin; T Guina; S H Jang; J F Tomayko; J Wang; L Zhuang; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 6.  Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Authors:  Jürgen B Bulitta; William W Hope; Ann E Eakin; Tina Guina; Vincent H Tam; Arnold Louie; George L Drusano; Jennifer L Hoover
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

7.  Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant Staphylococcus aureus Endovascular Infections?

Authors:  Warren Rose; Cecilia Volk; Thomas J Dilworth; George Sakoulas
Journal:  Open Forum Infect Dis       Date:  2022-04-09       Impact factor: 3.835

Review 8.  Efficacy and Safety of Daptomycin versus Vancomycin for Bacteremia Caused by Methicillin-Resistant Staphylococcus aureus with Vancomycin Minimum Inhibitory Concentration > 1 µg/mL: A Systematic Review and Meta-Analysis.

Authors:  Masaru Samura; Yuki Kitahiro; Sho Tashiro; Hiromu Moriyama; Yuna Hamamura; Isamu Takahata; Rina Kawabe; Yuki Enoki; Kazuaki Taguchi; Yoshio Takesue; Kazuaki Matsumoto
Journal:  Pharmaceutics       Date:  2022-03-27       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.